Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Investigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome

6 novembre 2026 mis à jour par: Emine Nacar, Inonu University

Polycystic ovary syndrome (PCOS) is a multisystemic disorder with metabolic and endocrine implications, commonly observed in women of reproductive age and characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Insulin resistance, chronic low-grade inflammation, hormonal imbalances, and obesity can contribute to reduced cardiorespiratory fitness and muscular endurance, in addition to the metabolic complications associated with PCOS. Furthermore, psychosocial effects such as depression, anxiety, and impaired quality of life may also occur. Lifestyle modifications and exercise are among the first-line approaches in the management of PCOS. Aerobic and resistance exercises have been reported to have positive effects on insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive functions. However, evidence regarding the specific effects of different exercise modalities on physical fitness components-such as cardiovascular and muscular endurance, which are adversely affected in PCOS-remains limited. Spinal stabilization exercises constitute an exercise approach aimed at enhancing core muscle strength and endurance, postural control, and movement quality by targeting deep trunk muscle activation, lumbopelvic stability, and neuromuscular control. Although studies exist regarding Pilates interventions targeting the core region in individuals with PCOS, no study has been found that examines the effects of spinal stabilization exercises administered either in isolation or as an adjunct to aerobic exercise. Therefore, it is hypothesized that incorporating spinal stabilization exercises into an aerobic exercise regimen may provide additional benefits-particularly regarding metabolic, hormonal, and inflammatory outcomes, alongside physical fitness components.

The aim of this study is to comparatively examine the effects of spinal stabilization exercises added to aerobic exercise-versus aerobic exercise alone-on metabolic, hormonal, and inflammatory markers, anthropometric characteristics, cardiovascular fitness, core muscle strength and endurance, and quality of life in individuals with PCOS.

Aperçu de l'étude

Statut

Inscription sur invitation

Description détaillée

Polycystic ovary syndrome (PCOS) is a common multisystem endocrine and metabolic disorder among women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. In addition to reproductive disturbances, PCOS is associated with insulin resistance, chronic low-grade inflammation, hormonal imbalances, obesity, and an increased risk of long-term metabolic complications. These alterations may also negatively affect physical fitness, particularly cardiorespiratory fitness and muscular endurance. Furthermore, PCOS may be accompanied by psychosocial problems, including depression and anxiety, which may contribute to impaired quality of life.

Lifestyle interventions, particularly physical activity and exercise, are considered first-line strategies in the management of PCOS. Aerobic and resistance exercise have been shown to improve insulin resistance, cardiometabolic risk factors, hormonal profiles, inflammation, body composition, and reproductive outcomes. However, evidence regarding their effects on physical fitness components that may be impaired in PCOS, particularly cardiorespiratory fitness and muscular endurance, remains limited. Moreover, there is no clear consensus regarding the specific effectiveness of different exercise modalities, contents, and training volumes on physical fitness outcomes in women with PCOS.

Spinal stabilization exercises focus on activating the deep trunk muscles and improving lumbopelvic stability, neuromuscular control, core muscle strength and endurance, postural control, and movement quality. Considering the adverse effects of insulin resistance, chronic inflammation, and hormonal disturbances on muscle morphology and physical fitness in PCOS, spinal stabilization exercises may provide additional benefits in this population. Although Pilates-based interventions targeting the core region have demonstrated beneficial effects on quality of life, hormonal profiles, menstrual symptoms, and certain physical fitness parameters in women with PCOS, the effects of spinal stabilization exercises, either alone or in combination with aerobic exercise, have not yet been investigated in this population. Therefore, adding spinal stabilization exercises to aerobic exercise may provide additional benefits for metabolic and hormonal functions, body composition, cardiorespiratory fitness, and muscular endurance.

The aim of this study is to compare the effects of aerobic exercise combined with spinal stabilization exercises versus aerobic exercise alone on metabolic, hormonal, and inflammatory markers, anthropometric parameters, cardiorespiratory fitness, core muscle strength, core muscle endurance, and quality of life in individuals with PCOS.

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Malatya
      • Malatya, Malatya, Turquie (Türkiye), 44280
        • Inönü University Department of Obstetrics and Gynecology

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 45 ans (Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Individuals aged 18-45 years (premenopausal) diagnosed with PCOS by an obstetrician-gynecologist, with a body mass index between 25 and 39.9 kg/m² and a physical activity level below 600 MET-min/week (inactive) according to the International Physical Activity Questionnaire-Short Form (IPAQ-SF) assessment.

Exclusion Criteria:

  • Pregnancy, diabetes, smoking, participation in a dietary intervention, congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia, Cushing's syndrome, or musculoskeletal disorders preventing exercise; use of antihypertensive medications, insulin-sensitizing drugs, nutritional supplements, or weight-loss medications

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: aerobic exercise group

The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods.

Expérimental: spinal stabilization exercise group combined with aerobic exercise

The aerobic training group will undergo aerobic exercise on a treadmill three days a week for eight weeks under the supervision of a specialist physiotherapist. For patients with no prior treadmill experience, the first session will serve as a trial session to facilitate adaptation to the treadmill. In subsequent sessions, the aerobic training will be conducted in phases comprising warm-up, exertion, and cool-down periods.

As a first step in spinal stabilization training, individuals will be instructed on proper postural alignment. To determine each individual's ideal posture, a neutral spine position-characterized by comfort and a lack of pain in the lumbopelvic region-will be identified in front of a mirror, and the contraction of deep muscles (abdominal bracing) will be taught. Individuals will be required to maintain proper posture and deep muscle group activation throughout the exercises. Stretching and mobility exercises targeting the lumbar region, trunk muscles, and lower extremities will be performed for approximately 5-10 minutes as part of the warm-up and cool-down periods surrounding the spinal stabilization exercises. The exercises will be conducted for approximately 30 minutes.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Fasting Blood Glucose Concentration
Délai: At baseline and after 8 weeks of treatment

Fasting blood glucose concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Fasting Serum Insulin Concentration
Délai: At baseline and after 8 weeks of treatment

Fasting serum insulin concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL.

At baseline and after 8 weeks of treatment
Fasting Serum Triglyceride Concentration
Délai: At baseline and after 8 weeks of treatment

Fasting serum triglyceride concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum High-Density Lipoprotein Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment

Serum high-density lipoprotein cholesterol (HDL-C) concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Low-Density Lipoprotein Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment

Serum low-density lipoprotein cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Total Cholesterol Concentration
Délai: At baseline and after 8 weeks of treatment

Serum total cholesterol concentration will be measured from venous blood samples after an overnight fast and reported in mg/dL.

At baseline and after 8 weeks of treatment
Serum Prolactin Concentration
Délai: At baseline and after 8 weeks of treatment

Serum prolactin concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL.

At baseline and after 8 weeks of treatment
Serum Luteinizing Hormone Concentration
Délai: At baseline and after 8 weeks of treatment

Serum luteinizing hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL.

At baseline and after 8 weeks of treatment
Serum Follicle-Stimulating Hormone Concentration
Délai: At baseline and after 8 weeks of treatment

Serum follicle-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in mIU/mL.

At baseline and after 8 weeks of treatment
Serum Thyroid-Stimulating Hormone Concentration
Délai: At baseline and after 8 weeks of treatment

Serum thyroid-stimulating hormone concentration will be measured from venous blood samples after an overnight fast and reported in µIU/mL.

At baseline and after 8 weeks of treatment
Serum High-Sensitivity C-Reactive Protein Concentration
Délai: At baseline and after 8 weeks of treatment

Serum high-sensitivity C-reactive protein concentration will be measured from venous blood samples after an overnight fast and reported in mg/L.

At baseline and after 8 weeks of treatment
Free Androgen Index
Délai: At baseline and after 8 weeks of treatment

Free androgen index will be calculated using total testosterone and sex hormone-binding globulin concentrations and reported as a dimensionless value.

At baseline and after 8 weeks of treatment
Serum Estradiol Concentration
Délai: At baseline and after 8 weeks of treatment

Serum estradiol concentration will be measured from venous blood samples after an overnight fast and reported in pg/mL.

At baseline and after 8 weeks of treatment
Serum Sex Hormone-Binding Globulin Concentration
Délai: At baseline and after 8 weeks of treatment

Serum sex hormone-binding globulin concentration will be measured from venous blood samples after an overnight fast and reported in nmol/L.

At baseline and after 8 weeks of treatment
Serum Anti-Müllerian Hormone Concentration
Délai: At baseline and after 8 weeks of treatment

Serum anti-Müllerian hormone concentration will be measured from venous blood samples after an overnight fast and reported in ng/mL.

At baseline and after 8 weeks of treatment
Homeostatic Model Assessment of Insulin Resistance
Délai: At baseline and after 8 weeks of treatment

Insulin resistance will be calculated using fasting glucose and fasting insulin concentrations according to the Homeostatic Model Assessment of Insulin Resistance formula and reported as an index value.

At baseline and after 8 weeks of treatment
Serum Interleukin-6 Concentration
Délai: At baseline and after 8 weeks of treatment

Serum interleukin-6 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and after 8 weeks of treatment
Serum Interleukin-10 Concentration
Délai: At baseline and 8 weeks after treatment.

Serum interleukin-10 concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and 8 weeks after treatment.
Serum Tumor Necrosis Factor-Alpha Concentration
Délai: At baseline and 8 weeks after treatment.

Serum tumor necrosis factor-alpha concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in pg/mL.

At baseline and 8 weeks after treatment.
Serum Adiponectin Concentration
Délai: At baseline and 8 weeks after treatment.

Serum adiponectin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL.

At baseline and 8 weeks after treatment.
Serum Irisin Concentration.
Délai: At baseline and 8 weeks after treatment.

Serum irisin concentration will be measured from venous blood samples using an enzyme-linked immunosorbent assay and reported in ng/mL.

At baseline and 8 weeks after treatment.
Waist-to-Hip Ratio
Délai: At baseline and 8 weeks after treatment

Waist circumference and hip circumference will be measured in meters (m). The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference.

At baseline and 8 weeks after treatment
Waist-to-Height Ratio
Délai: At baseline and 8 weeks after treatment

Waist circumference and height will be measured in meters (m). The waist-to-height ratio will be calculated by dividing waist circumference by height.

At baseline and 8 weeks after treatment
Anthropometric Measurement (Body Mass Index)
Délai: At baseline and 8 weeks after treatment

Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m².

At baseline and 8 weeks after treatment
Body Weight Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Body weight will be measured using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Fat Mass Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Body fat mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Fat Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Body fat percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Fat-Free Mass Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Fat-free mass will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Body Muscle Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Body muscle percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Total Body Water Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Total body water will be assessed using a Tanita bioelectrical impedance analysis device and reported in kilograms (kg).

At baseline and 8 weeks after treatment
Total Body Water Percentage Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Total body water percentage will be assessed using a Tanita bioelectrical impedance analysis device and reported as a percentage (%).

At baseline and 8 weeks after treatment
Visceral Fat Rating Assessed by Bioelectrical Impedance Analysis
Délai: At baseline and 8 weeks after treatment

Visceral fat will be assessed using a Tanita bioelectrical impedance analysis device and reported as the visceral fat rating provided by the device.

At baseline and 8 weeks after treatment
Cardiovascular fitness (6-minute walk test)
Délai: At baseline and 8 weeks after treatment

Cardiovascular fitness will be assessed using the 6-Minute Walk Test. Participants will be instructed to walk along a 30-meter corridor for 6 minutes at their usual walking pace. The total distance walked during 6 minutes will be recorded in meters (m).

At baseline and 8 weeks after treatment
Core muscle endurance (trunk flexor test)
Délai: At baseline and 8 weeks after treatment

Trunk flexor endurance will be assessed using the McGill Trunk Flexor Test. Participants will maintain the standardized trunk flexion position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and 8 weeks after treatment
Core muscle endurance (trunk extensor test)
Délai: At baseline and 8 weeks after treatment

Trunk extensor endurance will be assessed using the McGill Trunk Extensor Test. Participants will maintain the standardized horizontal trunk position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and 8 weeks after treatment
Core muscle endurance (side bridge test)
Délai: At baseline and after 8 weeks of treatment

Lateral trunk muscle endurance will be assessed using the Side Bridge Test. Participants will maintain the standardized side bridge position for as long as possible. The duration for which the position is maintained will be recorded in seconds (s).

At baseline and after 8 weeks of treatment
Core muscle strength (sit-up test)
Délai: At baseline and after 8 weeks of treatment

Core muscle strength will be assessed using the 30-second Sit-Up Test. Participants will perform as many sit-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded.

At baseline and after 8 weeks of treatment
Core muscle strength (Modified Push-up test)
Délai: At baseline and after 8 weeks of treatment

Core muscle strength will be assessed using the 30-second Modified Push-Up Test. Participants will perform as many modified push-ups as possible within 30 seconds. The total number of correctly completed repetitions will be recorded.

At baseline and after 8 weeks of treatment
Polycystic Ovary Syndrome Quality of Life-50 Scale
Délai: At baseline and after 8 weeks of treatment

Quality of life will be assessed using the Polycystic Ovary Syndrome Quality of Life-50 Scale. The scale consists of 50 items across six domains: psychosocial and emotional status, fertility, sexual function, obesity and menstrual disorders, hirsutism, and coping with the disease. Each item is scored from 1 to 5, with a total score ranging from 50 to 250. Higher total scores indicate better quality of life.

At baseline and after 8 weeks of treatment
Patient's Perception of Global Change
Délai: After 8 weeks of treatment

Participants' perceived change in polycystic ovary syndrome-related symptoms compared with baseline will be assessed using the Global Perceived Improvement Scale. The scale ranges from 1 to 7: 1 = very much better, 2 = much better, 3 = slightly better, 4 = no change, 5 = slightly worse, 6 = much worse, and 7 = very much worse. Lower scores indicate greater perceived improvement, whereas higher scores indicate greater perceived worsening.

After 8 weeks of treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 octobre 2026

Achèvement primaire (Estimé)

20 janvier 2027

Achèvement de l'étude (Estimé)

20 août 2027

Dates d'inscription aux études

Première soumission

30 septembre 2026

Première soumission répondant aux critères de contrôle qualité

6 octobre 2026

Première publication (Réel)

13 octobre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

6 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner